Pacific Edge faces setback: US court dismisses jurisdiction

Pacific Edge (NZX: PEB) announced that the US District Court for the Middle District of Pennsylvania has ruled it lacks jurisdiction to review the 'Genetic Testing in Oncology: Specific Tests' (L39365) Local Coverage Determination. This decision prevents the court from considering the merits of Pacific Edge's complaint filed in February. The company indicated the remaining avenue for L39365 not to become effective on April 24, 2025, is a policy action by the Center of Medicare and Medicaid Services (CMS). Pacific Edge is actively engaging with CMS and other relevant parties to advocate for the retirement or extension of the LCD's effective date. The company will provide further updates as more information becomes available.